GW Pharmaceuticals PLC represents values such as innovation, scientific excellence, and a commitment to improving the lives of patients through the development of prescription cannabinoid medicines. The company's corporate philosophy revolves around conducting rigorous scientific research, adhering to regulatory standards, and delivering high-quality therapies globally. GW Pharmaceuticals PLC believes in the potential of cannabinoids to address unmet medical needs, and their dedication to developing cutting-edge pharmaceutical formulations is reflected in their extensive clinical trial program. The company's focus on patient-centricity and collaboration with healthcare professionals underscores their mission to provide effective and safe treatment options to those in need.

GW Pharmaceuticals PLC is primarily present in multiple countries and regions. The company operates in the United States, where it is headquartered in Carlsbad, California. It also has a significant presence in the United Kingdom, with its main office located in Cambridge. Additionally, GW Pharmaceuticals PLC serves patients and healthcare professionals across Europe, including countries such as France, Germany, Spain, Italy, and the Netherlands. The company's presence extends to other parts of the world as well, as it operates in various regions across the globe.

GW Pharmaceuticals PLC has achieved several significant milestones. The company received approval from the U.S. Food and Drug Administration (FDA) for its cannabis-based drug Epidiolex in 2018, making it the first FDA-approved prescription medicine derived from the cannabis plant. This milestone marked a major breakthrough in the field of cannabinoid-based therapeutics. In addition, GW Pharmaceuticals PLC has successfully conducted clinical trials and obtained positive results for Epidiolex in treating severe forms of epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome. The company's dedication to research and development has positioned it as a leader in the pharmaceutical industry, with a focus on harnessing the therapeutic potential of cannabinoids.

GW Pharmaceuticals PLC is a renowned pharmaceutical company specializing in cannabinoid-based medicines. Established in 1998, the company has a rich history in researching, developing, and commercializing innovative therapies derived from botanical sources. GW Pharmaceuticals PLC has been a pioneer in advancing the understanding and medicinal potential of cannabinoids, particularly in the treatment of severe seizures associated with epilepsy. With a strong emphasis on scientific rigor, the company has successfully brought to market several breakthrough medications, such as Sativex and Epidiolex, which have significantly improved the lives of patients worldwide. GW Pharmaceuticals PLC continues to lead the field in developing novel treatments derived from cannabis-based compounds, earning recognition as a global leader in cannabinoid science and research.

The main competitors of GW Pharmaceuticals PLC in the market include companies such as AbbVie Inc., Tilray Inc., and Canopy Growth Corporation. These companies also operate in the pharmaceutical industry and focus on the development, manufacturing, and distribution of innovative medications and treatments. However, GW Pharmaceuticals PLC has a strong position in the market due to its expertise in cannabinoid-based pharmaceuticals and its flagship product, Epidiolex. With its groundbreaking research and focus on rare diseases, GW Pharmaceuticals PLC continues to differentiate itself from its competitors in the industry.

GW Pharmaceuticals PLC is primarily active in the pharmaceutical industry.

GW Pharmaceuticals PLC specializes in researching, developing, and commercializing novel cannabinoid prescription medicines. With a focus on developing pharmaceutical products derived from cannabis, the company aims to address unmet medical needs. GW Pharmaceuticals PLC follows a vertical integration model that spans the entire drug development process, from botanical research and cultivation to clinical trials and regulatory approvals. By utilizing its proprietary science and rigorous clinical research, GW Pharmaceuticals PLC aims to unlock the therapeutic potential of cannabinoids, thus improving the lives of patients suffering from various medical conditions.

GW Pharmaceuticals P/E suhe on 0,37.

GW Pharmaceuticals KUV on 49,11.

AlleAktien kvaliteediskoor ettevõttele GW Pharmaceuticals on 2/10.

oodatud GW Pharmaceuticals käive on 1,67 mld. USD.

oodatud GW Pharmaceuticals kasum on 222,56 mld. USD.

GW Pharmaceuticals is a British biopharmaceutical company specializing in the research, development, and marketing of medicines based on cannabis. The company was founded in 1998 and is headquartered in Cambridge, UK. It is listed on the NASDAQ since 2013. Its business model is based on the discovery of compounds in cannabis that have potential therapeutic benefits in medical treatment. The company focuses on processing plant cannabinoids, particularly THC and CBD, to create oral medications for patients. GW Pharmaceuticals has a wide portfolio of products, including Epidiolex, Sativex, and Epidyolex, which are all medications based on cannabinoids used for specific health issues such as epilepsy, multiple sclerosis, and spasticity. Its flagship product is Epidiolex, an oral solution approved for the treatment of rare forms of epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. GW Pharmaceuticals has expanded its presence in Europe and the world by entering into licensing partnerships for Sativex in various countries. The company has also signed distribution agreements for Epidiolex in Europe, Canada, and Australia. In addition to marketed medications, GW Pharmaceuticals is actively working on innovative solutions that can be used in the fields of oncology and neurology. The company conducts successful clinical trials for various conditions and diseases mainly attributed to the therapeutic benefits of cannabinoids. It is a commercial company focused on manufacturing and marketing medications, as well as a research company aiming to gain groundbreaking insights in the field of medical sciences and develop new drugs. They develop new products and conduct clinical studies to prove their efficacy and safety for regulatory approval by authorities such as the FDA. In summary, GW Pharmaceuticals specializes in the research and development of cannabis-based medications. The company strives to discover the medical potential of cannabinoids and develop innovative solutions for severe and rare diseases. GW Pharmaceuticals has a strong research and development department and collaborates with licensing partners to ensure the availability of its products worldwide.

GW Pharmaceuticals maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu GW Pharmaceuticals jaoks arvutada või ettevõte ei maksa dividende välja.

GW Pharmaceuticals ISIN on US36197T1034.

GW Pharmaceuticals WKN on A1T980.

GW Pharmaceuticals tähis on GWPH.

Viimase 12 kuu jooksul maksis GW Pharmaceuticals dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab GW Pharmaceuticals tõenäoliselt dividendi summas 0 USD.

GW Pharmaceuticals praegune dividenditootlus on .

GW Pharmaceuticals maksab kvartaalset dividendi. See makstakse välja kuudel .

GW Pharmaceuticals maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

GW Pharmaceuticals on liigitatud sektorisse 'Tervis'.

Viimase GW Pharmaceuticals dividendide saamiseks 19.1.2025 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 19.1.2025.

Viimane dividendimakse toimus 19.1.2025.

Aastal 2024 maksis GW Pharmaceuticals 0 USD dividende.

GW Pharmaceuticals dividendid makstakse välja USD.